Karin Burnett

2021-10-07T13:51:10+01:00

Meet The Team

Dr Karin Burnett | Toxicologist | ApconiX

Dr Karin Burnett

PhD, DABT

Karin is a toxicologist with extensive experience of drug safety having worked for a number of pharmaceutical companies including Zeneca, SmithKline Beechams and Shire Pharmaceuticals.  More recently Karin has worked with Public Health England and Imperial College, London (Toxicology Unit) as a scientific writer compiling detailed literature reviews on a wide variety of subjects for the government advisory Committees on Carcinogenicity (COC) and Mutagenicity (COM).  Karin brings depth and breadth of experience gained from the application of toxicology in diverse sectors.

Read more here

Professor Ruth Roberts | Director | ApconiX
Ruth Roberts
Richard Knight | Director | ApconiX
Richard Knight
Michael Morton | Director | ApconiX
Mike Morton

Laurence Bishop

2021-10-07T13:49:18+01:00

Meet The Team

Dr Laurence Bishop Head of Business Development

Dr Laurence Bishop

PhD

Laurence is an experienced DMPK and toxicological Scientist, with 20 years of non-clinical drug development and chemical experience at medium and large CROs as well as within AstraZeneca. Specialising in Business Development for the last 13 years Laurence combines a passion for appropriate pharmaceutical development and a knowledge of project scientific and commercial needs. he is well placed to support both our customers and Apconix to best deliver non-clinical safety programmes. Laurence has a proven track record for communication, ownership, integrity and delivery, building mutually beneficial and lasting customer relationships.

Read more here

Professor Ruth Roberts | Director | ApconiX
Ruth Roberts
Richard Knight | Director | ApconiX
Richard Knight
Dr Mike Morton
Mike Morton

Kemal Haque

2021-09-29T12:10:01+01:00

Meet The Team

Kemal Haque | ApconiX

Kemal Haque

PhD

Kemal is a toxicologist with 20 years’ experience supporting biopharma projects from early discovery through clinical development. He has experience across different therapeutic areas, target classes, and modalities (small molecule and biologics) and has worked in both small biotech and large pharma organisations. Kemal has a track record of delivering timely, fit-for-purpose toxicology data packages, on budget and successfully devising and executing critical path risk mitigation strategies

Peter Ballard437
Peter Ballard
Annette Zaar | Toxicologist | ApconiX
Annette Zaar
Drug safety
Drug Project Toxicology

Tanya Coleman

2021-10-07T10:20:22+01:00

Meet The Team

Tanya square

Tanya Coleman

PhD

Tanya has more than 20 years’ experience in pharmaceutical project teams as a nonclinical ADME specialist and clinical pharmacologist. She held project and team leader roles at several large pharma companies before becoming an independent consultant.  In these roles, she has supported research teams as well as early and late clinical development projects, with a particular strength in oncology and infection.  Tanya has also led specialist groups in in vitro metabolism and drug transporters.

Kemal Hague
Kemal Haque
Richard Knight | Director | ApconiX
Richard Knight
Drug safety
Drug Project Toxicology

Sanofi

2020-09-14T17:47:25+01:00

“The target safety evaluation was perfect.  Our toxicologist was very happy with the final document as was the project team.  Not only was the document great, it was delivered on time and the turn-around time for the edits was outstanding.  I have no doubt that we will be using your services in the future.”

James Murray, Toxicologist, Sanofi

Leading Global Pharmaceutical Company

2020-01-23T09:22:46+00:00

“I wanted to let you know that, after including your expert report into the IB, the Health Authority have approved both the IB as well as the clinical protocol amendment switching the contraception method from highly affective to effective, without any further questions or comments.

This is a very good news for the project, and clinical studies can continue as planned. Thank you very much for all your support, it was a great pleasure collaborating with you. I have greatly appreciated your thorough assessment as well as responsive and friendly  manner, and your input made a key difference for the project progression.”

Preclinical Project Manager, Leading Global Pharmaceutical Company

Olivia Turner

2021-10-07T13:46:50+01:00

Meet The Team

olivia 450

Olivia Turner

BSc

Olivia has recently completed her second year studying Biomedical Sciences at Sheffield University. Choosing to take the Physiology and Pharmacology route in her second year, Olivia is currently on a placement year (jointly with ApconiX and Aptus Clinical) to gain greater understanding of drug development and the pharmaceutical industry. She hopes to be able to finish her degree and move straight to studying for a Ph.D. Versatile, enthusiastic and highly adaptive, Olivia is a great addition to the ApconiX office as she learns about the essential role of drug safety in pharmaceuticals as well as what it’s like to be part of a growing company.

Read more here

William O'Brien | Finance Advisor | ApconiX
William O’Brien
Julie Knight | Finance Manager | ApconiX
Julie Knight
Louisa Lake | Admin and Finance | ApconiX
Louisa Lake

Andrew Winkley

2021-09-29T12:16:31+01:00

Meet The Team

andrew 800

Andrew Winkley

PhD, DABT

Andrew has over 20 years of drug safety experience in industry at AstraZeneca and Vertex. He has a broad scientific background that includes mechanistic and regulatory toxicology, and biochemistry. His drug development experience covers the complete life cycle of drug development from discovery to late-stage development in several therapeutic areas including orphan indications, neuroscience, pain therapeutics, inflammatory diseases, infectious diseases, and oncology. Andrew has been involved in bringing several candidate molecules to clinical trials and most recently completed an NDA/MAA for a cystic fibrosis drug. Andrew is a highly adaptive project toxicologist who can assimilate and interpret a broad range of data from various disciplines to provide clear guidance to the project team.

Claire Sadler | Toxicologist | ApconiX
Claire Sadler
Russell Huby | Target Safety Assessments | ApconiX
Russell Huby
Acuity Image
Target Safety Assessments

Paul Duffy

2021-10-07T10:40:37+01:00

Meet The Team

Paul Duffy | ApconiX

Dr Paul Duffy

PhD, ERT, FBTS

Paul is senior project toxicologist with particular expertise in new modalities including RNA therapeutics and regenerative medicines. He is an extremely highly experienced project toxicologist with invaluable submission experience in multiple territories including repurposing of existing drug projects for new applications. He has served on the BTS Executive Committee since 2006, and has many publications in peer reviewed journals. Paul is former senior project toxicologist at AstraZeneca and a former board member of Stem cells for Safer Medicines (SC4SM).

Jane Barber | Toxicologist | ApconiX
Jane Barber
Damian
Damian Deavall
Drug safety
Drug Project Toxicology

Annette Zaar

2021-10-07T10:48:04+01:00

Meet The Team

annette2 533

Dr Annette Zaar-Hartmann

PhD

Annette is a senior bioanalytics and PKPD expert with 13 years of experience in the early development of biologics. Annette has worked across multiple therapy areas and on multiple biologics modalities including mAbs, mAb-constructs, Fabs, fusion proteins, peptides and vaccines. She is former Head of Immungenicity, former Head of Bioanalytics for Biologics and former PKPD Expert for Biologics at Novartis. Annette brings an understanding of integrated assay development for PK, PD and anti-drug antibodies as well as expertise in data interpretation and the subsequent development of a tailored PKPD strategy for biologics projects.

Richard Knight | Director | ApconiX
Richard Knight
Professor Ruth Roberts | Director | ApconiX
Ruth Roberts
Drug safety
Drug Project Toxicology